Association of Systemic Sclerosis With a Unique Colonic Microbial ConsortiumOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study compared the colonic microbial composition of patients with systemic sclerosis (SSc) to that of healthy controls. Researchers used 16S ribosomal RNA sequencing on mucosal lavage samples collected from the cecum and sigmoid colon during colonoscopy. They also examined whether specific bacterial genera were associated with the presence and severity of gastrointestinal tract symptoms in the SSc patients.
Who was studied?
The study included 17 adult patients with systemic sclerosis, 88 percent of whom were female, with a median age of 52.1 years. Healthy controls were matched to the SSc patients by age and sex on a one-to-one basis. Gastrointestinal symptom burden in the SSc group was assessed with the GI Tract 2.0 score, which averaged 0.7 with a standard deviation of 0.6.
What were the most important findings?
Principal coordinate analysis showed significant differences in microbial community structure between SSc patients and healthy controls in both the cecum and sigmoid regions. Patients with SSc had decreased levels of commensal bacteria such as Faecalibacterium and Clostridium, a pattern similar to that seen in other inflammatory disease states. The abstract text provided is cut off before detailing which genera were increased in SSc patients or which specific genera correlated with GI symptoms, so those findings cannot be reported here.
What are the greatest implications of this study?
The findings suggest that systemic sclerosis is associated with a distinct colonic microbial consortium that departs from that of healthy individuals, marked by loss of beneficial commensal genera. Because this shift parallels patterns observed in other inflammatory conditions, it raises the possibility that the gut microbiome contributes to or reflects the inflammatory processes underlying SSc. This supports further investigation into the colonic microbiota as a potential factor in SSc-related gastrointestinal symptoms and as a possible target for future research or intervention.